Global Nontuberculous Mycobacterium Treatment 麻豆原创 Research Report 2023

Publication ID:

PB501236037

Publication Date:

January 10, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Highlights
The global Nontuberculous Mycobacterium Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Nontuberculous Mycobacterium Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Nontuberculous Mycobacterium Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Nontuberculous Mycobacterium Treatment in Hospitals Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Nontuberculous Mycobacterium Treatment include Insmed Incorporated, RedHill Biopharma, Novoteris, Savara and Beyond Air, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nontuberculous Mycobacterium Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nontuberculous Mycobacterium Treatment.
The Nontuberculous Mycobacterium Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nontuberculous Mycobacterium Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nontuberculous Mycobacterium Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Insmed Incorporated
RedHill Biopharma
Novoteris
Savara
Beyond Air
Segment by Type
Azithromycin
Rifampin
Rifabutin
Ethambuto
Segment by Application
Hospitals Pharmacies
Private clinics
Drug Stores and Retail Pharmacy
E-commerce
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nontuberculous Mycobacterium Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Azithromycin
1.2.3 Rifampin
1.2.4 Rifabutin
1.2.5 Ethambuto
1.3 麻豆原创 by Application
1.3.1 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals Pharmacies
1.3.3 Private clinics
1.3.4 Drug Stores and Retail Pharmacy
1.3.5 E-commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Perspective (2018-2029)
2.2 Nontuberculous Mycobacterium Treatment Growth Trends by Region
2.2.1 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nontuberculous Mycobacterium Treatment Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Nontuberculous Mycobacterium Treatment Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Nontuberculous Mycobacterium Treatment 麻豆原创 Dynamics
2.3.1 Nontuberculous Mycobacterium Treatment Industry Trends
2.3.2 Nontuberculous Mycobacterium Treatment 麻豆原创 Drivers
2.3.3 Nontuberculous Mycobacterium Treatment 麻豆原创 Challenges
2.3.4 Nontuberculous Mycobacterium Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nontuberculous Mycobacterium Treatment Players by Revenue
3.1.1 Global Top Nontuberculous Mycobacterium Treatment Players by Revenue (2018-2023)
3.1.2 Global Nontuberculous Mycobacterium Treatment Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nontuberculous Mycobacterium Treatment Revenue
3.4 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Nontuberculous Mycobacterium Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nontuberculous Mycobacterium Treatment Revenue in 2022
3.5 Nontuberculous Mycobacterium Treatment Key Players Head office and Area Served
3.6 Key Players Nontuberculous Mycobacterium Treatment Product Solution and Service
3.7 Date of Enter into Nontuberculous Mycobacterium Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Nontuberculous Mycobacterium Treatment Breakdown Data by Type
4.1 Global Nontuberculous Mycobacterium Treatment Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Nontuberculous Mycobacterium Treatment Forecasted 麻豆原创 Size by Type (2024-2029)
5 Nontuberculous Mycobacterium Treatment Breakdown Data by Application
5.1 Global Nontuberculous Mycobacterium Treatment Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Nontuberculous Mycobacterium Treatment Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Nontuberculous Mycobacterium Treatment 麻豆原创 Size (2018-2029)
6.2 North America Nontuberculous Mycobacterium Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2018-2023)
6.4 North America Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nontuberculous Mycobacterium Treatment 麻豆原创 Size (2018-2029)
7.2 Europe Nontuberculous Mycobacterium Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2018-2023)
7.4 Europe Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nontuberculous Mycobacterium Treatment 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Nontuberculous Mycobacterium Treatment 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nontuberculous Mycobacterium Treatment 麻豆原创 Size (2018-2029)
9.2 Latin America Nontuberculous Mycobacterium Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nontuberculous Mycobacterium Treatment 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Nontuberculous Mycobacterium Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Nontuberculous Mycobacterium Treatment 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Insmed Incorporated
11.1.1 Insmed Incorporated Company Detail
11.1.2 Insmed Incorporated Business Overview
11.1.3 Insmed Incorporated Nontuberculous Mycobacterium Treatment Introduction
11.1.4 Insmed Incorporated Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.1.5 Insmed Incorporated Recent Development
11.2 RedHill Biopharma
11.2.1 RedHill Biopharma Company Detail
11.2.2 RedHill Biopharma Business Overview
11.2.3 RedHill Biopharma Nontuberculous Mycobacterium Treatment Introduction
11.2.4 RedHill Biopharma Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.2.5 RedHill Biopharma Recent Development
11.3 Novoteris
11.3.1 Novoteris Company Detail
11.3.2 Novoteris Business Overview
11.3.3 Novoteris Nontuberculous Mycobacterium Treatment Introduction
11.3.4 Novoteris Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.3.5 Novoteris Recent Development
11.4 Savara
11.4.1 Savara Company Detail
11.4.2 Savara Business Overview
11.4.3 Savara Nontuberculous Mycobacterium Treatment Introduction
11.4.4 Savara Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.4.5 Savara Recent Development
11.5 Beyond Air
11.5.1 Beyond Air Company Detail
11.5.2 Beyond Air Business Overview
11.5.3 Beyond Air Nontuberculous Mycobacterium Treatment Introduction
11.5.4 Beyond Air Revenue in Nontuberculous Mycobacterium Treatment Business (2018-2023)
11.5.5 Beyond Air Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Insmed Incorporated
RedHill Biopharma
Novoteris
Savara
Beyond Air

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.